10X GENOMICS INC-CLASS A (TXG)
US88025U1097 - Common Stock
Taking everything into account, TXG scores 4 out of 10 in our fundamental rating. TXG was compared to 55 industry peers in the Life Sciences Tools & Services industry. While TXG has a great health rating, there are worries on its profitability. While showing a medium growth rate, TXG is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
TXG had negative earnings in the past year.
TXG had a positive operating cash flow in the past year.
TXG had negative earnings in each of the past 5 years.
TXG had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
TXG has a Return On Assets of -19.47%. This is in the lower half of the industry: TXG underperforms 61.82% of its industry peers.
Looking at the Return On Equity, with a value of -25.26%, TXG is in line with its industry, outperforming 43.64% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -19.47% | ||
| ROE | -25.26% | ||
| ROIC | N/A |
ROA(3y)-16.09%
ROA(5y)-22.37%
ROE(3y)-20.72%
ROE(5y)-28.6%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of TXG (66.63%) is better than 96.36% of its industry peers.
In the last couple of years the Gross Margin of TXG has declined.
The Profit Margin and Operating Margin are not available for TXG so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 66.63% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.32%
GM growth 5Y-3.84%
2. Health
2.1 Basic Checks
TXG does not have a ROIC to compare to the WACC, probably because it is not profitable.
TXG has more shares outstanding than it did 1 year ago.
TXG has more shares outstanding than it did 5 years ago.
TXG has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
TXG has an Altman-Z score of 3.05. This indicates that TXG is financially healthy and has little risk of bankruptcy at the moment.
TXG has a Altman-Z score of 3.05. This is in the better half of the industry: TXG outperforms 61.82% of its industry peers.
There is no outstanding debt for TXG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 3.05 |
ROIC/WACCN/A
WACC11.28%
2.3 Liquidity
TXG has a Current Ratio of 4.90. This indicates that TXG is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.90, TXG is in the better half of the industry, outperforming 74.55% of the companies in the same industry.
A Quick Ratio of 4.12 indicates that TXG has no problem at all paying its short term obligations.
With a decent Quick ratio value of 4.12, TXG is doing good in the industry, outperforming 69.09% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.9 | ||
| Quick Ratio | 4.12 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 19.90% over the past year.
The Revenue has been growing slightly by 6.57% in the past year.
The Revenue has been growing by 33.43% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)19.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.03%
Revenue 1Y (TTM)6.57%
Revenue growth 3Y27.46%
Revenue growth 5Y33.43%
Sales Q2Q%-1.3%
3.2 Future
Based on estimates for the next years, TXG will show a very strong growth in Earnings Per Share. The EPS will grow by 24.66% on average per year.
The Revenue is expected to grow by 12.60% on average over the next years. This is quite good.
EPS Next Y34.45%
EPS Next 2Y19.75%
EPS Next 3Y17.64%
EPS Next 5Y24.66%
Revenue Next Year-2.87%
Revenue Next 2Y1.53%
Revenue Next 3Y4.09%
Revenue Next 5Y12.6%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
TXG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TXG. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Price/Free Cash Flow ratio of TXG indicates a somewhat cheap valuation: TXG is cheaper than 61.82% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 69.17 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as TXG's earnings are expected to grow with 17.64% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.75%
EPS Next 3Y17.64%
5. Dividend
5.1 Amount
No dividends for TXG!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
10X GENOMICS INC-CLASS A
NASDAQ:TXG (11/22/2024, 8:10:11 PM)
After market: 14.5 +0.19 (+1.33%)14.31
+1.02 (+7.67%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.73B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -19.47% | ||
| ROE | -25.26% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 66.63% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.67
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.9 | ||
| Quick Ratio | 4.12 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)19.9%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y34.45%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)6.57%
Revenue growth 3Y27.46%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y